HTH-01-091

Overview

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase ( MELK ) inhibitor, with an IC 50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3 , RIPK2 , DYRK3 , smMLCK and CLK2 . HTH-01-091 can be uesd for breast cancer research.

Application

Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Pim | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > CDK | Products > Signaling Pathways > GSK-3 | Products > Signaling Pathways > RIP kinase | Products > Signaling Pathways > MELK | Products > Signaling Pathways > DYRK

Product Information

• Catalog No.: HY-122665
• CAS No.: 2000209-42-5
• Molecular Formula: C26H28Cl2N4O2
• Molecular Weight: 499.43
• Purity: 99.81%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (2.50 mM); Clear solution
• Availability: In-stock

Source

Original product source